Transforming R&D with Generative AI and Real-World Data

Ryan Fukushima, Chief Operating Officer at Tempus, and Robert Shoemaker, Ph.D., Senior Vice President of Research at Erasca, Inc., spoke about the transformative power of artificial intelligence in oncology research and drug development at the AACR Annual Meeting 2025.

Jul 01, 2025
Life Sciences
Video
Ryan FukushimaChief Operating Officer, Tempus
Robert Shoemaker, Ph.D.Senior Vice President, Research at Erasca, Inc.

Related content

Simple white graphic of a single sheet of paper or document, slightly angled.Article
Person works on computer with abstract digital code and data patterns overlayed.

Constructing clinical timelines with line of therapy

Life Sciences
Simple white graphic of a single sheet of paper or document, slightly angled.Article
Light background with faint, pixelated letters resembling DNA or digital code.

Designing smarter trials: A new model for clinical development

2026-04-28
Life Sciences
Simple white graphic of a single sheet of paper or document, slightly angled.Article
Abstract image with blurred geometric cubes and DNA sequences on a light background.

How biotechs can build a data-driven R&D strategy

2026-04-27
Life Sciences